ACTRN12611000030976Active, not recruiting未知
The Effects of Delta 9-tetrahydrocannabinol (THC) on Driving Performance, Cognition, Fatigue and Stress on Healthy Volunteers.
Securetec0 sites20 target enrollmentStarted: January 10, 2011Last updated:
Trial Snapshot
- Phase
- 未知
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 20
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 21 Years to 40 Years (—)
- Sex
- All
Inclusion Criteria
- •Experienced cannabis smoker
- •Holder of full Driver's License
Exclusion Criteria
- •History of substance abuse or dependence for any drug; Known allergic reaction to cannabis in the past ; Chronic Cannabis user; Wears glasses or spectacles to read/use a computer (contact lenses okay);
- •History of psychiatric illnesses, especially Anxiety/Depression, Schizophrenia, Bipolar Disorder &/or Psychosis; Pregnant, lactating, or potentially pregnant; History of the following medical conditions: Cardiovascular conditions, Respiratory conditions, Endocrine conditions, Gastrointestinal conditions, Bleeding disorders, Neurological disorders, Liver or kidney conditions, Brain injury or Traumatic Head Injury or prolonged periods of unconsciousness; Currently taking prescription medication (other than a contraceptive pill)
Investigators
Similar Trials
Completed
Not Applicable
The effects of inhaled delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) on pain relief and subjective effects in fibromyalgia patients - A placebo controlled PKPD studychronische pijnchronic painpainNL-OMON42607eids Universitair Medisch Centrum20
Not yet recruiting
Phase 2
Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) effects on perception of illusions, schizotypy and cognition in healthy volunteersMental Health - SchizophreniaPsychosisCannabis use safetyMental Health - Psychosis and personality disordersMental Health - Studies of normal psychology, cognitive function and behaviourSchizophreniaACTRN12621000469819niversity of Western Australia36
Completed
Phase 2
Efficacy and safety of delta-9-tetrahydrocannabinol (delta-THC) in behavioural disturbances in dementiaAlzheimer's diseaseDementiaNL-OMON39470niversitair Medisch Centrum Sint Radboud150
Active, not recruiting
Phase 1
THC in behavioural problems and pain in dementiaSubjects with mild to severe Alzheimer's dementia and/or vascular dementia with behavioural disturbances, with at least agitation, aggression or aberrant motor disturbances.MedDRA version: 16.1Level: PTClassification code 10012271Term: Dementia Alzheimer's typeSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 16.1Level: PTClassification code 10057678Term: Vascular dementiaSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 16.1Level: PTClassification code 10033371Term: PainSystem Organ Class: 10018065 - General disorders and administration site conditionsMedDRA version: 16.1Level: PTClassification code 10012267Term: DementiaSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 16.1Level: PTClassification code 10066842Term: Behavioural and psychiatric symptoms of dementiaSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2011-005289-39-NLRadboud university medical center150
Completed
Not Applicable
Acute and delayed effects of THC intoxication on false memories in a legal contextno health condition is addressed in the research, and healthy volunteers who are occasional cannabis users will be recruitedn.a.NL-OMON45359niversiteit Maastricht40